What is the recommended duration of anticoagulation therapy for a first episode of deep‑vein thrombosis (DVT) in provoked, unprovoked, cancer‑associated, and recurrent cases?

Duration of Anticoagulation for Deep Vein Thrombosis

All patients with DVT require a minimum of 3 months of therapeutic anticoagulation, with duration beyond this determined by whether the DVT was provoked or unprovoked, the location (proximal vs. distal), and individual bleeding risk. 1

Provoked DVT (Reversible Risk Factors)

Stop anticoagulation at 3 months for DVT provoked by transient risk factors such as surgery or trauma. 1

• Patients with DVT provoked by surgery have an annual recurrence risk <1% after completing 3 months of treatment 1
• Extended anticoagulation beyond 3 months is not routinely required for provoked DVT 1
• For hormone-associated DVT, discontinue hormonal therapy before stopping anticoagulation at 3 months 1
• Research confirms that reducing treatment from 3 months to 1 month increases recurrence risk without meaningful reduction in bleeding 2

Unprovoked Proximal DVT

Continue anticoagulation indefinitely (with no scheduled stop date) for unprovoked proximal DVT in patients with low to moderate bleeding risk. 1, 3

• Unprovoked venous thrombosis carries an annual recurrence risk >5% after stopping anticoagulation, which substantially outweighs bleeding risk in appropriate patients 1, 3
• The initial 3-6 months addresses the acute thrombotic event, with 6 months offering lower early recurrence risk than 3 months 1
• After completing 6 months of full-dose therapy, consider reduced-dose DOACs (apixaban 2.5 mg twice daily or rivaroxaban 10 mg once daily) for extended treatment to further reduce bleeding risk 1, 3
• Research demonstrates that extended anticoagulation prevents recurrence during treatment, but benefit disappears after stopping therapy 4

Unprovoked Distal (Calf) DVT

For unprovoked isolated distal DVT not extending into the popliteal vein, 3 months of anticoagulation is sufficient. 1

• Isolated distal DVT has approximately half the recurrence risk of proximal DVT and a low risk of recurrent VTE presenting as PE 1, 3
• Anticoagulant therapy beyond 3 months is not required for calf DVT 1

Cancer-Associated DVT

Continue anticoagulation indefinitely for cancer-associated DVT, at least until resolution of the underlying malignancy. 1

• Patients with active cancer represent a permanent risk factor requiring ongoing anticoagulation 1

Bleeding Risk Assessment for Extended Therapy

Low to Moderate Bleeding Risk (Suitable for Indefinite Anticoagulation):

• Age <70 years 1, 3
• No previous major bleeding episodes 1, 3
• No concomitant antiplatelet therapy 1, 3
• No severe renal or hepatic impairment 1, 3
• Good medication adherence 1, 3

High Bleeding Risk (Stop at 3 Months):

• Age ≥80 years 1
• Previous major bleeding 1
• Recurrent falls 1
• Need for dual antiplatelet therapy 1
• Severe renal or hepatic impairment 1

Ongoing Management

Reassess all patients on indefinite anticoagulation at least annually, evaluating bleeding risk factors, medication adherence, patient preference, hepatic and renal function, and drug tolerance. 1, 3, 5

Critical Pitfalls to Avoid

• Do not fail to distinguish between proximal and distal DVT when making duration decisions, as this leads to inappropriate treatment 1
• Do not treat all VTE cases identically without considering provoked vs. unprovoked status 1
• Do not use fixed time-limited periods beyond 3 months (such as 6 or 12 months) for unprovoked proximal DVT—the choice is either 3 months or indefinite based on bleeding risk 1
• Do not base anticoagulation decisions on the presence of chronic/residual thrombus on ultrasound, as this does not mandate continued therapy; the original circumstances of the VTE determine duration 1
• Do not stop anticoagulation prematurely before completing at least 3 months, as this increases early recurrence risk 5